Company news

Neurogene Inc. news in 2024

Neurogene Inc.'s news releases, calls and decks from 2024, newest first.

View company

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

November 17, 2024

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

November 17, 2024

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

November 10, 2024

Neurogene Announces Oversubscribed $200 Million Private Placement

November 3, 2024

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

October 20, 2024

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

August 8, 2024

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

August 6, 2024

Neurogene to Participate in BMO Genetic Medicines Summit

July 1, 2024

Neurogene Announces Addition to Russell 3000® Index

June 30, 2024

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

June 17, 2024

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

June 2, 2024

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

May 9, 2024

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

May 6, 2024

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

April 21, 2024

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

March 17, 2024

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

March 3, 2024

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

January 15, 2024

Neurogene Announces Business Update and 2024 Outlook

January 4, 2024

Decks in 2024